West Oak Capital Has Increased By $91.89 Million Its Avery Dennison (AVY) Stake; 683 Capital Management Upped Fate Therapeutics (FATE) Holding

Avery Dennison Corporation (NYSE:AVY) Logo

683 Capital Management Llc increased Fate Therapeutics Inc (FATE) stake by 25.78% reported in 2017Q4 SEC filing. 683 Capital Management Llc acquired 175,000 shares as Fate Therapeutics Inc (FATE)’s stock rose 82.53%. The 683 Capital Management Llc holds 853,800 shares with $5.22 million value, up from 678,800 last quarter. Fate Therapeutics Inc now has $489.73 million valuation. The stock decreased 6.92% or $0.69 during the last trading session, reaching $9.28. About 448,490 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 112.01% since April 9, 2017 and is uptrending. It has outperformed by 100.46% the S&P500.

West Oak Capital Llc increased Avery Dennison Corp (AVY) stake by 114.29% reported in 2017Q4 SEC filing. West Oak Capital Llc acquired 800 shares as Avery Dennison Corp (AVY)’s stock declined 8.51%. The West Oak Capital Llc holds 1,500 shares with $172.29M value, up from 700 last quarter. Avery Dennison Corp now has $9.09B valuation. The stock decreased 2.71% or $2.87 during the last trading session, reaching $103.2. About 963,544 shares traded or 36.16% up from the average. Avery Dennison Corporation (NYSE:AVY) has risen 31.20% since April 9, 2017 and is uptrending. It has outperformed by 19.65% the S&P500.

Investors sentiment increased to 1.05 in 2017 Q4. Its up 0.13, from 0.92 in 2017Q3. It increased, as 25 investors sold AVY shares while 180 reduced holdings. 79 funds opened positions while 137 raised stakes. 69.57 million shares or 0.73% less from 70.08 million shares in 2017Q3 were reported. Arizona State Retirement Systems stated it has 0.03% in Avery Dennison Corporation (NYSE:AVY). Spears Abacus Advsr Limited Liability Corp owns 1,884 shares or 0.03% of their US portfolio. Riverhead Capital Management Ltd Liability Co, a Delaware-based fund reported 6,767 shares. 4,400 are owned by Spectrum Gp Incorporated. Service Automobile Association holds 134,293 shares or 0.04% of its portfolio. Nelson Van Denburg & Campbell Wealth Mgmt Gru Limited Liability owns 0.07% invested in Avery Dennison Corporation (NYSE:AVY) for 2,660 shares. Us Bankshares De has 58,667 shares for 0.02% of their portfolio. Ct Mason holds 49,444 shares. Sg Americas Lc holds 0.02% or 16,700 shares. Wellington Gp Ltd Liability Partnership holds 0% of its portfolio in Avery Dennison Corporation (NYSE:AVY) for 10,535 shares. Systematic Financial Mgmt Ltd Partnership holds 0.25% or 107,798 shares. Guardian Life Ins Of America reported 286 shares. Clinton Gru owns 24,664 shares. Fjarde Ap accumulated 28,699 shares. Brinker Capital accumulated 4,158 shares or 0.02% of the stock.

West Oak Capital Llc decreased Gilead Sciences Inc (NASDAQ:GILD) stake by 1,895 shares to 2,791 valued at $199.95 million in 2017Q4. It also reduced Mc Cormick & Co Inc N (NYSE:MKC) stake by 380 shares and now owns 3,525 shares. Danaher Corp Del (NYSE:DHR) was reduced too.

Among 11 analysts covering Avery Dennison (NYSE:AVY), 5 have Buy rating, 2 Sell and 4 Hold. Therefore 45% are positive. Avery Dennison has $140 highest and $66 lowest target. $117.67’s average target is 14.02% above currents $103.2 stock price. Avery Dennison had 37 analyst reports since October 15, 2015 according to SRatingsIntel. The stock of Avery Dennison Corporation (NYSE:AVY) earned “Underweight” rating by JP Morgan on Thursday, February 1. The firm has “Hold” rating given on Tuesday, March 27 by BMO Capital Markets. The stock of Avery Dennison Corporation (NYSE:AVY) has “Sell” rating given on Friday, March 16 by J.P. Morgan. As per Friday, May 20, the company rating was downgraded by JP Morgan. The stock has “Underperform” rating by Bank of America on Friday, July 1. Barclays Capital maintained the stock with “Overweight” rating in Monday, May 2 report. Robert W. Baird maintained Avery Dennison Corporation (NYSE:AVY) rating on Wednesday, January 10. Robert W. Baird has “Buy” rating and $125.0 target. On Wednesday, June 21 the stock rating was maintained by KeyBanc Capital Markets with “Hold”. The firm has “Hold” rating by KeyBanc Capital Markets given on Friday, February 2. Bank of America upgraded Avery Dennison Corporation (NYSE:AVY) on Tuesday, June 20 to “Buy” rating.

Since October 27, 2017, it had 0 insider buys, and 10 sales for $17.82 million activity. $3.31M worth of Avery Dennison Corporation (NYSE:AVY) was sold by SCARBOROUGH DEAN A. Hill Anne had sold 21,134 shares worth $2.50 million. Butier Mitchell R also sold $889,275 worth of Avery Dennison Corporation (NYSE:AVY) shares. Another trade for 2,000 shares valued at $229,510 was sold by BARKER PETER K. Shares for $376,753 were sold by Miller Susan C. 2,770 shares valued at $325,466 were sold by Anderson Anthony on Wednesday, February 14.

Among 10 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Fate Therapeutics had 20 analyst reports since October 6, 2015 according to SRatingsIntel. The company was maintained on Wednesday, December 13 by H.C. Wainwright. Piper Jaffray maintained Fate Therapeutics, Inc. (NASDAQ:FATE) rating on Tuesday, March 6. Piper Jaffray has “Buy” rating and $20.0 target. The stock has “Outperform” rating by Wells Fargo on Friday, December 4. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) has “Outperform” rating given on Tuesday, November 8 by Wedbush. The firm earned “Outperform” rating on Tuesday, April 12 by BMO Capital Markets. The stock has “Buy” rating by Roth Capital on Thursday, September 22. Raymond James initiated the shares of FATE in report on Tuesday, October 6 with “Outperform” rating. The stock of Fate Therapeutics, Inc. (NASDAQ:FATE) earned “Hold” rating by H.C. Wainwright on Tuesday, March 20. H.C. Wainwright maintained the shares of FATE in report on Thursday, March 29 with “Hold” rating. The rating was downgraded by Raymond James to “Hold” on Tuesday, March 6.

Investors sentiment decreased to 1.58 in Q4 2017. Its down 0.21, from 1.79 in 2017Q3. It is negative, as 9 investors sold FATE shares while 17 reduced holdings. 17 funds opened positions while 24 raised stakes. 32.27 million shares or 31.43% more from 24.55 million shares in 2017Q3 were reported. Rhumbline Advisers has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE). The Massachusetts-based Numeric Investors Limited has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Moreover, J Goldman Co LP has 0.07% invested in Fate Therapeutics, Inc. (NASDAQ:FATE). Schwab Charles Investment holds 0% or 66,000 shares in its portfolio. Parallax Volatility Advisers Ltd Partnership holds 5,796 shares or 0% of its portfolio. Vanguard Grp holds 0% or 1.46M shares in its portfolio. Royal National Bank & Trust Of Canada reported 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Redmile Gru Limited Liability Corporation invested in 1.46% or 5.47M shares. Interest reported 0% stake. Tci Wealth Advsrs has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 1,525 shares. Macquarie Limited invested in 0% or 1,800 shares. State Of Wisconsin Investment Board invested in 30,000 shares. Bridgeway Management Inc reported 256,000 shares. Ameritas Inv Prns holds 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE) for 3,346 shares. Deutsche Financial Bank Ag invested in 0% or 86,531 shares.

Since October 13, 2017, it had 0 buys, and 3 insider sales for $148,927 activity. Wolchko J Scott sold $66,600 worth of stock. The insider TAHL CINDY sold 8,091 shares worth $31,124. On Friday, October 13 the insider Shoemaker Daniel D sold $51,203.

683 Capital Management Llc decreased Etsy Inc stake by 50,000 shares to 700,000 valued at $14.32M in 2017Q4. It also reduced Enova Intl Inc stake by 50,600 shares and now owns 843,200 shares. Pepsico Inc (Put) (NYSE:PEP) was reduced too.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart